Literature DB >> 10733887

Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris.

M P Byrne1, R W Titball, J Holley, L A Smith.   

Abstract

A recombinant vaccine candidate was developed that protected mice against botulinum neurotoxin serotype F (BoNTF) intoxication. A synthetic gene encoding BoNTF fragment C (rBoNTF(H(c))) was designed, constructed, and inserted into a plasmid for expression in the yeast Pichia pastoris. A total cell protein content of 2.9 g was obtained per liter of fermentation broth. Recombinant rBoNTF(H(c)) was purified from the soluble yeast extract in two chromatographic steps. The process employed Mono S cation exchange chemistry followed by Alkyl-Superose hydrophobic interaction chromatography, producing material judged to be greater than 98% pure by SDS-PAGE. The recovery of purified product from cell extract was estimated to be greater than 42%, with a yield of 140 mg/kg of cell paste. rBoNTF(H(c)) was also purified from the insoluble fraction of the yeast cell lysate. Because the fragment C in the pellet was 35% of the total insoluble protein, only a Mono S cation exchange chromatography step was necessary to achieve a purity greater than 98%. Mice that received three injections of 0.2 microgram of purified soluble rBoNTF(H(c)) were completely protected when challenged with 1000 mouse ip LD(50) of BoNTF toxin. Similarly, three doses of 1 microgram of purified resolubilized rBoNTF(H(c)) completely protected mice from a challenge of 5000 mouse ip LD(50) of BoNTF toxin. Individual serum antibody ELISA titers of mice injected with soluble rBoNTF(H(c)) correlated with survival as all 34 mice with ELISA titers of 100 or greater survived toxin challenge. The work presented here demonstrates that purified rBoNTF(H(c)) is able to protect against a high challenge dose of neurotoxin. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10733887     DOI: 10.1006/prep.2000.1200

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  13 in total

1.  Recombinant holotoxoid vaccine against botulism.

Authors:  Christina L Pier; William H Tepp; Marite Bradshaw; Eric A Johnson; Joseph T Barbieri; Michael R Baldwin
Journal:  Infect Immun       Date:  2007-10-29       Impact factor: 3.441

2.  Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system.

Authors:  R Zichel; A Mimran; A Keren; A Barnea; I Steinberger-Levy; D Marcus; A Turgeman; S Reuveny
Journal:  Clin Vaccine Immunol       Date:  2010-03-31

3.  Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E.

Authors:  Dan-Yang Shi; Fu-Jia Liu; Yun-Yun Mao; Rong-Tian Cui; Jian-Sheng Lu; Yun-Zhou Yu; Xiao-Jie Dong; Zhi-Xin Yang; Zhi-Wei Sun; Xiao-Bin Pang
Journal:  Hum Vaccin Immunother       Date:  2019-07-26       Impact factor: 3.452

4.  Characterization of neutralizing antibodies and identification of neutralizing epitope mimics on the Clostridium botulinum neurotoxin type A.

Authors:  H C Wu; C T Yeh; Y L Huang; L J Tarn; C C Lung
Journal:  Appl Environ Microbiol       Date:  2001-07       Impact factor: 4.792

5.  Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine.

Authors:  Yun-Zhou Yu; Na Li; Rui-Lin Wang; Heng-Qi Zhu; Shuang Wang; Wei-Yuan Yu; Zhi-Wei Sun
Journal:  Clin Vaccine Immunol       Date:  2008-10-08

6.  The receptor binding domain of botulinum neurotoxin serotype A (BoNT/A) inhibits BoNT/A and BoNT/E intoxications in vivo.

Authors:  Alon Ben David; Eran Diamant; Ada Barnea; Osnat Rosen; Amram Torgeman; Ran Zichel
Journal:  Clin Vaccine Immunol       Date:  2013-06-12

7.  Recombinant production of bacterial toxins and their derivatives in the methylotrophic yeast Pichia pastoris.

Authors:  Cemal Gurkan; David J Ellar
Journal:  Microb Cell Fact       Date:  2005-12-07       Impact factor: 5.328

8.  Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo.

Authors:  Andrew W Hudacek; Fetweh H Al-Saleem; Mallory Willet; Travis Eisemann; Jeffrey A Mattis; Lance L Simpson; Matthias J Schnell
Journal:  Mol Ther Methods Clin Dev       Date:  2014-10-01       Impact factor: 6.698

9.  Intratracheal inoculation of AHc vaccine induces protection against aerosolized botulinum neurotoxin A challenge in mice.

Authors:  Changjiao Gan; Wenbo Luo; Yunzhou Yu; Zhouguang Jiao; Sha Li; Duo Su; Junxia Feng; Xiaodong Zhao; Yefeng Qiu; Lingfei Hu; Dongsheng Zhou; Xiaolu Xiong; Jinglin Wang; Huiying Yang
Journal:  NPJ Vaccines       Date:  2021-06-22       Impact factor: 7.344

10.  Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism.

Authors:  Robert P Webb; Theresa J Smith; Leonard A Smith; Patrick M Wright; Rebecca L Guernieri; Jennifer L Brown; Janet C Skerry
Journal:  Toxins (Basel)       Date:  2017-09-03       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.